Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
What happens to skin cells when they are confronted with blood? A team of researchers from Oslo University Hospital, led by Emma Lång and Stig Ove Bøe, performed experiments on blood-deprived cells that were subsequently exposed to blood serum. Remarkably, all the cells started to move and grow in the same direction as soon as the blood serum was added. Assistant Professor Liesbeth Janssen and student Marijke Valk from Eindhoven University of Technology (TU/e) developed a matching simulation model, revealing new insights into the mechanisms of wound healing. The results have recently been published in the journal Nature Communications.
On Monday September 3rd professor Harald Stenmark from the Department of Molecular Biology at the Institute for Cancer Research will receive the prestigious University of Oslo Research Award for 2018 during the annual anniversary party in the University Aula. Stenmark has been interviewed by Martin Toft for the UiO newpaper Uniforum, where his very successful ongoing career is chronicled. The article is entitled "Hunting for the Achilles heels of Cancer". Together with other award winners Stenmark gave a short lecture about his research in the library in the Vilhelm Bjerknes building the same Monday.
Thomas Fleischer and Xavier Tekpli from the Cancer Genome Variation group, led by Vessela Kristensen at the Department of Cancer Genetics, IKF, together with their collaborators from the NCMM, Toni Hurtado and Anthony Mathelier, and Professor Arnoldo Frigessi from UiO identified methylated regions (CpGs) that show remarkably and reproducibly conserved patterns of association to gene expression in the DNA from breast tumors in three independent breast cancer cohorts. The article - entitled “DNA methylation at enhancers identifies distinct breast cancer lineages” has been selected for the Editors’ Highlights webpage of recent research on Genomes and Epigenomes, put together by the editors at Nature Communications.
Imatinib treatment has been very successful in gastrointestinal stromal tumour (GIST), where an initial treatment response is seen for the majority of the patients. However, over time the tumours evolve and get resistant to the treatment. GISTs are characterised by mutations in tyrosine kinase receptors KIT and PDGFRA, which are important for treatment decisions. There is a need to establish patient-friendly means/methods to obtain tumour material for mutational testing, which can ultimately improve the treatment of GIST patients.
The second ERC Advanced Grant to Professor Harald Stenmark, director of the Centre of Excellence “Centre for Cancer Cell Reprogramming” at the Institute of Clinical Medicine, UiO, and head of the "Cellular membrane dynamics" group and the Department of Molecular Cell Biology, Institute for Cancer Research, OUH was celebrated on 22nd of August.
Through this prestigious grant from the European Research Council, Stenmark's research project "Coincidence detection of proteins and lipids in regulation of cellular membrane dynamics (CODE)" is supported with 2.5 million Euros over a 5-year period.
Tumor hypoxia promotes metastasis and resistance to radiotherapy in prostate cancer. An imaging method to assess hypoxia at diagnosis can help to select patients for intensified treatment and avoid overtreatment of indolent, low-risk disease; but has not been successfully developed for this disease. In this paper, postdocTord Hompland in Heidi Lyng's group at Department of Radiation Biology and his co-workers present a novel method to visualize hypoxia based on diagnostic, multiparametric diffusion weighted MR images (DW-MRI). The work is part of an ongoing collaboration between the group and the FuncProst research team, headed by Therese Seierstad and Knut Håkon Hole at Division of Radiology and Nuclear Medicine at OUS. The method can easily be translated into clinical practice, and a large scale, prospective evaluation of the method is planned for prostate cancer.